{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:12Z","timestamp":1791316752384,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2023834"],"award-info":[{"award-number":["BE2023834"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073308"],"award-info":[{"award-number":["82073308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373105"],"award-info":[{"award-number":["82373105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114348","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:33:40Z","timestamp":1761089620000},"page":"114348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Enhancing cisplatin therapy for small cell lung cancer via a dual strategy of combining surufatinib and CD47 blockade"],"prefix":"10.1016","volume":"388","author":[{"given":"Kaiming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huae","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114348_bb0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.114348_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.jconrel.2025.114348_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0020","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.114348_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2016.04.014","article-title":"A phase I trial of the hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer","volume":"99","author":"Pietanza","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2025.114348_bb0030","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","article-title":"A highly annotated database of genes associated with platinum resistance in cancer","volume":"40","author":"Huang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114348_bb0035","doi-asserted-by":"crossref","unstructured":"A.K.P. Ganti, B.W. Loo, M. Bassetti, C. Blakely, A. Chiang, T.A. D'Amico, C. D'Avella, A. Dowlati, R.J. Downey, M. Edelman, C. Florsheim, K.A. Gold, J.W. Goldman, J.C. Grecula, C. Hann, W. Iams, P. Iyengar, K. Kelly, M. Khalil, M. Koczywas, R.E. Merritt, N. Mohindra, J. Molina, C. Moran, S. Pokharel, S. Puri, A. Qin, C. Rusthoven, J. Sands, R. Santana-Davila, M. Shafique, S.N. Waqar, K.M. Gregory, M. Hughes, Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw. 19 (2021) 1441\u20131464.","DOI":"10.6004\/jnccn.2021.0058"},{"key":"10.1016\/j.jconrel.2025.114348_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0045","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7150\/thno.89805","article-title":"Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer","volume":"14","author":"Zhu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114348_bb0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/jacs.1c09753","article-title":"Phototheranostic metal-phenolic networks with Antiexosomal PD-L1 enhanced Ferroptosis for synergistic immunotherapy","volume":"144","author":"Xie","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.114348_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","article-title":"Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114348_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211042689","article-title":"Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)","volume":"13","author":"Xu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0065","article-title":"Surufatinib in neuroendocrine tumours","volume":"20","author":"Das","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-024-01974-2","article-title":"Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib\/II trial","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114348_bb0075","doi-asserted-by":"crossref","first-page":"1288255","DOI":"10.3389\/fphar.2024.1288255","article-title":"Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6_Supplement","key":"10.1016\/j.jconrel.2025.114348_bb0080","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/1538-7445.AM2024-2122","article-title":"Abstract 2122: enhanced anticancer efficacy via ROS-dependent ferroptosis: synergy between surufatinib and cisplatin in small cell lung cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114348_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10120-024-01574-7","article-title":"Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition","volume":"28","author":"Wang","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/mm9.0000000000000004","article-title":"Metalloptosis: metal ions-induced programmed cell death based on nanomaterials for cancer therapy","volume":"1","author":"Wang","year":"2024","journal-title":"MedMat"},{"key":"10.1016\/j.jconrel.2025.114348_bb0095","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.114348_bb0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2017.01.003","article-title":"The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation","volume":"106","author":"Iriki","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2025.114348_bb0105","doi-asserted-by":"crossref","first-page":"1158857","DOI":"10.3389\/fonc.2023.1158857","article-title":"Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion dual role in tumor cells and tumor microenvironment","volume":"13","author":"Liao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0110","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114348_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-023-00418-4","article-title":"Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition","volume":"7","author":"Al-Sudani","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0125","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41418-022-01008-w","article-title":"Wnt\/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2025.114348_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.171","article-title":"JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry","volume":"3","author":"Perelman","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.114348_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41419-023-06045-y","article-title":"The diversified role of mitochondria in ferroptosis in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.114348_bb0140","doi-asserted-by":"crossref","first-page":"eaaw7843","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"27","key":"10.1016\/j.jconrel.2025.114348_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505000","article-title":"Engineered bacterial outer membrane vesicles hitchhiking on neutrophils for antibody drug delivery to enhance postoperative immune checkpoint therapy","volume":"12","author":"Guan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.114348_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114348_bb0155","article-title":"Ferroptosis in Cancer treatment: another way to Rome","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0160","doi-asserted-by":"crossref","first-page":"2107529","DOI":"10.1002\/adfm.202107529","article-title":"Ultrasound-augmented nanocatalytic ferroptosis reverses chemotherapeutic resistance and induces synergistic tumor nanotherapy","volume":"32","author":"Zheng","year":"2022","journal-title":"Adv. Funct. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114348_bb0165","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114348_bb0170","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","article-title":"Glutaminolysis and transferrin regulate Ferroptosis","volume":"59","author":"Gao","year":"2015","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114348_bb0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41565-019-0419-9","article-title":"Winning the war with iron","volume":"14","author":"Torti","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114348_bb0180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting Ferroptosis to Iron out Cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"issue":"51","key":"10.1016\/j.jconrel.2025.114348_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904197","article-title":"Recent Progress in Ferroptosis inducers for Cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114348_bb0190","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41419-021-04490-1","article-title":"Double-edge sword roles of iron in driving energy production versus instigating ferroptosis","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114348_bb0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41419-024-07244-x","article-title":"Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications","volume":"15","author":"Zheng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.114348_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114203","article-title":"Outer membrane vesicle-coated ferrocene nanoparticles induce dual ferroptosis for cancer immunotherapy","volume":"387","author":"Shen","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0210","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s12885-023-11230-5","article-title":"Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114348_bb0215","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114348_bb0220","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114348_bb0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-019-1166-3","article-title":"Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src\/CD155\/MIF functional pathway","volume":"38","author":"Huang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.jconrel.2025.114348_bb0235","doi-asserted-by":"crossref","unstructured":"H. Li, P. Yang, J. Wang, J. Zhang, Q. Ma, Y. Jiang, Y. Wu, T. Han, D. Xiang, HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk, J. Hematol. Oncol. 15(1) (2022) 2.","DOI":"10.1186\/s13045-021-01223-x"},{"key":"10.1016\/j.jconrel.2025.114348_bb0240","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114348_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202403108","article-title":"NIR-II photoacoustic imaging-guided chemo-Photothermal therapy using PA1094T combined with anti-CD47 antibody: activating Pyroptosis against Orthotopic glioblastoma","volume":"14","author":"Li","year":"2025","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114348_bb0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41419-025-07779-7","article-title":"SIRP\u03b1 blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Cell Death Dis."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:07:51Z","timestamp":1769868471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S0168365925009629"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114348","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing cisplatin therapy for small cell lung cancer via a dual strategy of combining surufatinib and CD47 blockade","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114348"}}